Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://chandlerchamber.com](https://www.archivebay.com/archive6/images/f06cef40-b002-49ed-aa41-994b160a3670.png)
A complete backup of https://chandlerchamber.com
Are you over 18 and want to see adult content?
![A complete backup of https://mathmammoth.com](https://www.archivebay.com/archive6/images/93bc4b15-da5a-4388-8b3b-d4f6b922116a.png)
A complete backup of https://mathmammoth.com
Are you over 18 and want to see adult content?
![A complete backup of https://sbchamber.org](https://www.archivebay.com/archive6/images/fd0ad800-4d1a-4699-b1b8-9bb68d269afd.png)
A complete backup of https://sbchamber.org
Are you over 18 and want to see adult content?
![A complete backup of https://shop-swimmingpool.de](https://www.archivebay.com/archive6/images/163b8b85-780a-4805-8065-76b859514727.png)
A complete backup of https://shop-swimmingpool.de
Are you over 18 and want to see adult content?
![A complete backup of https://langen.de](https://www.archivebay.com/archive6/images/4db9eced-cd29-474f-93e3-3b231d35fb20.png)
A complete backup of https://langen.de
Are you over 18 and want to see adult content?
![A complete backup of https://chriscoxforcongress.com](https://www.archivebay.com/archive6/images/6b774db9-3531-448c-8892-65aed6198e7b.png)
A complete backup of https://chriscoxforcongress.com
Are you over 18 and want to see adult content?
![A complete backup of https://niseko-ta.jp](https://www.archivebay.com/archive6/images/eb1a3922-a7cc-4cf4-9d3d-1520fdf5225b.png)
A complete backup of https://niseko-ta.jp
Are you over 18 and want to see adult content?
![A complete backup of https://veganosity.com](https://www.archivebay.com/archive6/images/1b64e5cf-3a61-4930-8bd3-86f9971d98cc.png)
A complete backup of https://veganosity.com
Are you over 18 and want to see adult content?
![A complete backup of https://waxpoetics.com](https://www.archivebay.com/archive6/images/29c8602b-e2ea-412b-b19b-3eb7e3e322e4.png)
A complete backup of https://waxpoetics.com
Are you over 18 and want to see adult content?
![A complete backup of https://secondhome.nl](https://www.archivebay.com/archive6/images/78687f55-c288-4477-8e31-237b2b7bfe95.png)
A complete backup of https://secondhome.nl
Are you over 18 and want to see adult content?
![A complete backup of https://scamforex.net](https://www.archivebay.com/archive6/images/10f0d8b9-40eb-4807-835b-6bdcfc56a2c8.png)
A complete backup of https://scamforex.net
Are you over 18 and want to see adult content?
![A complete backup of https://pitt.biz](https://www.archivebay.com/archive6/images/b7d39957-2fd8-4b74-a0eb-d2f78d09198c.png)
A complete backup of https://pitt.biz
Are you over 18 and want to see adult content?
Favourite Annotations
![A complete backup of https://northweststoragesolutions.co.uk](https://www.archivebay.com/archive6/images/f060e420-0b2c-4680-a1ad-4355e85ae603.png)
A complete backup of https://northweststoragesolutions.co.uk
Are you over 18 and want to see adult content?
![A complete backup of https://weblistposting.com](https://www.archivebay.com/archive6/images/c8a14351-f9e4-49d9-8a68-54130ac69629.png)
A complete backup of https://weblistposting.com
Are you over 18 and want to see adult content?
![A complete backup of https://chicopeema.gov](https://www.archivebay.com/archive6/images/3f357125-c9de-4481-94df-c738abe04536.png)
A complete backup of https://chicopeema.gov
Are you over 18 and want to see adult content?
![A complete backup of https://backcountrybinders.com](https://www.archivebay.com/archive6/images/fc564eec-9ecb-42fc-bcb7-3cbf0e506d5d.png)
A complete backup of https://backcountrybinders.com
Are you over 18 and want to see adult content?
![A complete backup of https://innovasys.com](https://www.archivebay.com/archive6/images/cb3e618a-cf27-4e2a-bbeb-020289c14768.png)
A complete backup of https://innovasys.com
Are you over 18 and want to see adult content?
![A complete backup of https://youserdrivenmedia.net](https://www.archivebay.com/archive6/images/63d89465-50d0-4ea2-b281-08418d836a4b.png)
A complete backup of https://youserdrivenmedia.net
Are you over 18 and want to see adult content?
![A complete backup of https://johntaylorgatto.com](https://www.archivebay.com/archive6/images/7c969d6d-1c20-4a40-8d9b-863f34c5206d.png)
A complete backup of https://johntaylorgatto.com
Are you over 18 and want to see adult content?
![A complete backup of https://tollygirls.com](https://www.archivebay.com/archive6/images/dc7383b4-393c-42a8-b915-8391b3bb2327.png)
A complete backup of https://tollygirls.com
Are you over 18 and want to see adult content?
![A complete backup of https://mshsaa.org](https://www.archivebay.com/archive6/images/0d888098-6538-4712-bf87-1cd2c2710c01.png)
A complete backup of https://mshsaa.org
Are you over 18 and want to see adult content?
![A complete backup of https://op-terschelling.nl](https://www.archivebay.com/archive6/images/d53e0854-0a54-4e82-8ec5-3de3762d7b79.png)
A complete backup of https://op-terschelling.nl
Are you over 18 and want to see adult content?
![A complete backup of https://hilariousworld.org](https://www.archivebay.com/archive6/images/9bd55b22-eef3-4b62-818c-fde4ad819925.png)
A complete backup of https://hilariousworld.org
Are you over 18 and want to see adult content?
![A complete backup of https://fccchina.org](https://www.archivebay.com/archive6/images/e036fbef-3c2c-4c75-b506-bcfb14b5a0db.png)
A complete backup of https://fccchina.org
Are you over 18 and want to see adult content?
Text
worldwide.
OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883 NOVARTIS PHARMACEUTICALS A-Z Myfortic (mycophenolic acid (as mycophenolate sodium)) Immunosuppressant. Consumer Information. Product Monograph. Important information for healthcare professionals (2009) Public Communication (2009) Important information for health care professionals (2016) CAREERS | NOVARTIS CANADA Novartis is a global healthcare company based in Switzerland that provides solutions to the evolving needs of patients worldwide.PRODUCT MONOGRAPH
Page 1 of 52 PRODUCT MONOGRAPH PrMEKINIST® Trametinib Tablets 0.5 mg, 1.0 mg and 2.0 mg Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd.PRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. NOVARTIS CANADACHANGEDIRECTIONSWEBSITE1 FOURSQUARE TIPDIRECTIONSWEBSITE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patientsworldwide.
OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883 NOVARTIS PHARMACEUTICALS A-Z Myfortic (mycophenolic acid (as mycophenolate sodium)) Immunosuppressant. Consumer Information. Product Monograph. Important information for healthcare professionals (2009) Public Communication (2009) Important information for health care professionals (2016) CAREERS | NOVARTIS CANADA Novartis is a global healthcare company based in Switzerland that provides solutions to the evolving needs of patients worldwide.PRODUCT MONOGRAPH
Page 1 of 52 PRODUCT MONOGRAPH PrMEKINIST® Trametinib Tablets 0.5 mg, 1.0 mg and 2.0 mg Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd.PRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada.NOVARTIS CANADA
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patientsworldwide.
NOVARTIS PHARMACEUTICALS A-Z Myfortic (mycophenolic acid (as mycophenolate sodium)) Immunosuppressant. Consumer Information. Product Monograph. Important information for healthcare professionals (2009) Public Communication (2009) Important information for health care professionals (2016) NOVARTIS IN CANADA RESPONDS TO COVID-19 WITH COMMITMENTS As the unprecedented impact of the COVID-19 pandemic continues to be felt across the country, Novartis in Canada which includes the Innovative Medicines Division (Oncology and Pharma business units) and Sandoz Canada, is focused on helping Canadians with what they need now and into the future as we adapt to life with COVID-19. DISCOVERY | NOVARTIS CANADA This site is intended for an audience in Canada. NOVARTIS RECEIVES HEALTH CANADA APPROVAL FOR MAYZENTTM Mayzent TM (siponimod) is the first oral treatment approved for people living with secondary progressive multiple sclerosis (SPMS) with active disease, and the first treatment approved for SPMS with active disease in almost 15 years 1; Most people living with relapsing remitting MS (RRMS) will develop SPMS 2 ; Approval is based on the Phase III EXPAND trial, the largest controlled clinicalPRODUCT MONOGRAPH
Page 1 of 41 PRODUCT MONOGRAPH PrVOLTAREN* VOLTAREN* SR (diclofenac sodium) 50 mg Enteric-Coated Tablets 75 and 100 mg Slow-Release Tablets 50 and 100 mg Suppositories PRTASIGNA - NOVARTIS Page 4 of 69 Geriatrics (≥ 65 years of age): Approximately 12% and 30% of subjects in the clinical studies (Phase III study (A2303) in newly diagnosed Ph+ CML-CP; and Phase II study (A2101) in resistant or -intolerant Ph+ CML-CP and CML-AP) were 65 years of age or olderrespectively.
PRJADENU - NOVARTIS
PRODUCT MONOGRAPH PrJADENU® Deferasirox Tablets 90 mg, 180 mg, 360 mg Iron chelating agent Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd., Dorval, Quebec, H9S 1A9 PRZOFRAN TABLETS, ORAL SOLUTION AND INJECTION Page 3 of 39 PrZOFRAN® Tablets, Oral Solution and Injection (ondansetron hydrochloride dihydrate) PrZOFRAN® ODT (Oral Disintegrating Tablets) (ondansetron) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of PART III: CONSUMER INFORMATION SANDOSTATIN WAS WHAT IMPORTANT: PLEASE READ have problems with your blood sugar levels, either too high or too low (hypoglycaemia), a)have gallstones or have had gallstones in the past, as prolonged use of SANDOSTATIN® may result in gallstone formation, have problems with your liver (e.g. liver cirrhosis), down into the bottom portion of the ampoule.OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775NOUS CONTACTER
Pour les consommateurs. Pour des questions médicales au sujet de nos produits pharmaceutiques, SVP contactez notre ligne d’info médicaleau 1-800-363-8883.
HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. [PRODUCT MONOGRAPH TEMPLATE Page 1 of 51 PRODUCT MONOGRAPH Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking ACCESSIBILITY FOR ONTARIANS WITH DISABILITIES STATEMENT OF Accessibility for Ontarians with Disabilities Statement of Commitment The goal of the Accessibility for Ontarians with Disabilities Act, 2005 (“AODA”) is to create a more accessible Ontario by identifying, and to the extent possible, preventing and eliminating PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775NOUS CONTACTER
Pour les consommateurs. Pour des questions médicales au sujet de nos produits pharmaceutiques, SVP contactez notre ligne d’info médicaleau 1-800-363-8883.
HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. [PRODUCT MONOGRAPH TEMPLATE Page 1 of 51 PRODUCT MONOGRAPH Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking ACCESSIBILITY FOR ONTARIANS WITH DISABILITIES STATEMENT OF Accessibility for Ontarians with Disabilities Statement of Commitment The goal of the Accessibility for Ontarians with Disabilities Act, 2005 (“AODA”) is to create a more accessible Ontario by identifying, and to the extent possible, preventing and eliminating PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883 NOVARTIS PHARMACEUTICALS A-Z IZBA (Travoprost ophthalmic solution) Elevated Intraocular Pressure Therapy. Patient Medication Information. Product Monograph. NOVARTIS PHARMACEUTICALS A-Z Myfortic (mycophenolic acid (as mycophenolate sodium)) Immunosuppressant. Consumer Information. Product Monograph. Important information for healthcare professionals (2009) Public Communication (2009) Important information for health care professionals (2016)GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775 HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 52 PRODUCT MONOGRAPH PrMEKINIST® Trametinib Tablets 0.5 mg, 1.0 mg and 2.0 mg Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd.PRODUCT MONOGRAPH
3 Distribution Peak plasma concentrations of 10.8 and 7.8 ng/mL were observed, on average, 2 hours after administration of 0.30 mg/kg in children and adults, respectively. PRODUCT MONOGRAPH CLOZARIL PRODUCT MONOGRAPH PrCLOZARIL® (Clozapine Tablets) 25 mg and 100 mg Antipsychotic Agent Novartis Pharmaceuticals Canada Inc. DATE OF REVISION: 385 boul. Bouchard August 26, 2015 [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775NOUS CONTACTER
Pour les consommateurs. Pour des questions médicales au sujet de nos produits pharmaceutiques, SVP contactez notre ligne d’info médicaleau 1-800-363-8883.
HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. [PRODUCT MONOGRAPH TEMPLATE Page 1 of 51 PRODUCT MONOGRAPH Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking ACCESSIBILITY FOR ONTARIANS WITH DISABILITIES STATEMENT OF Accessibility for Ontarians with Disabilities Statement of Commitment The goal of the Accessibility for Ontarians with Disabilities Act, 2005 (“AODA”) is to create a more accessible Ontario by identifying, and to the extent possible, preventing and eliminating PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775NOUS CONTACTER
Pour les consommateurs. Pour des questions médicales au sujet de nos produits pharmaceutiques, SVP contactez notre ligne d’info médicaleau 1-800-363-8883.
HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 59 PRODUCT MONOGRAPH Pr XOLAIR® (omalizumab) Sterile powder for reconstitution, 150 mg vial Solution for injection, 75 mg and 150mg pre-filled syringe PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION … Page 2 of 91 What is a Notice of Compliance with Conditions (NOC/c)? An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada. [PRODUCT MONOGRAPH TEMPLATE Page 1 of 51 PRODUCT MONOGRAPH Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking ACCESSIBILITY FOR ONTARIANS WITH DISABILITIES STATEMENT OF Accessibility for Ontarians with Disabilities Statement of Commitment The goal of the Accessibility for Ontarians with Disabilities Act, 2005 (“AODA”) is to create a more accessible Ontario by identifying, and to the extent possible, preventing and eliminating PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"OUR PRODUCTS
For Consumers For medical questions about our pharmaceuticals products, please contact our Med Info line at 1-800-363-8883 NOVARTIS PHARMACEUTICALS A-Z IZBA (Travoprost ophthalmic solution) Elevated Intraocular Pressure Therapy. Patient Medication Information. Product Monograph. NOVARTIS PHARMACEUTICALS A-Z Myfortic (mycophenolic acid (as mycophenolate sodium)) Immunosuppressant. Consumer Information. Product Monograph. Important information for healthcare professionals (2009) Public Communication (2009) Important information for health care professionals (2016)GENERAL CONTACT
Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec H9S 1A9 (514) 631-6775 HEALTH CANADA APPROVES KESIMPTA®, THE FIRST AND ONLY SELF Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing remitting multiple sclerosis (RRMS) 1 Approval is based on two Phase III studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRIPRODUCT MONOGRAPH
Page 1 of 52 PRODUCT MONOGRAPH PrMEKINIST® Trametinib Tablets 0.5 mg, 1.0 mg and 2.0 mg Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd.PRODUCT MONOGRAPH
3 Distribution Peak plasma concentrations of 10.8 and 7.8 ng/mL were observed, on average, 2 hours after administration of 0.30 mg/kg in children and adults, respectively. PRODUCT MONOGRAPH CLOZARIL PRODUCT MONOGRAPH PrCLOZARIL® (Clozapine Tablets) 25 mg and 100 mg Antipsychotic Agent Novartis Pharmaceuticals Canada Inc. DATE OF REVISION: 385 boul. Bouchard August 26, 2015 [PRODUCT MONOGRAPH TEMPLATE SEEBRI® BREEZHALER® Product Monograph Page 4 of 34 WARNINGS AND PRECAUTIONS General Not for Acute use SEEBRI® BREEZHALER® is a once-daily long-term maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy. When beginning treatment with SEEBRI® BREEZHALER®, patients who have been taking PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ Page 1 of 4 PART III: CONSUMER INFORMATION N FIORINAL®-C 1/4, 1/2 (acetylsalicylic acid-caffeine-codeine-butalbital) This leaflet is part III of a three-part "Product Monograph"Close
* Skip to main navigation * Skip to main content* Skip to Footer
Google Tag Manager
* English
* Français
* Canada
* Novartis Site Directory * Our Work show submenu for Our Work* Our Process
* Clinical Trials
* Clinical Pipeline
* Product Portfolio
* About Us show submenu for About Us* Who We Are
* Our Business
* Corporate Responsibility* Contact Us
* AODA Compliant
* Grants and Donations* AMA Compliant
* Biome Canada, Montreal * Our Products show submenu for Our Products* Pharmaceuticals
* Health Care Professional* For Consumers
* News show submenu for News* Media Releases
* Media Contacts
* Stories
* FAQ
* Careers show submenu for Careers* Careers Search
* Working at Novartis* Employee Benefits
* Student Programs
Search
HOMEPAGE
THE NOVARTIS BIOME
A catalyst for impactful digital collaborationRead More
NOVARTIS IN CANADA RESPONDS TO COVID-19 WITH COMMITMENTS IN KEY AREAS Our primary concern at Novartis remains the health and safety of our associates and patients globally ...Read More
Stories / Discovery MAKING HISTORY IN BLOOD CANCER FOR DECADES Novartis making history in blood cancer for decadesRead More
THE NOVARTIS COMMITMENT TO PATIENTS AND CAREGIVERS We recognize the importance of patients and caregivers understanding what they can expect from Novartis.Read More
Products
Pharmaceuticals
Explore
News
Media Releases
Explore
About Us
Grants and DonationsExplore
Careers
Careers Search
Explore
Featured / Jan 26
NOVARTIS 2020 FINANCIAL RESULTS Novartis announced fourth quarter and full year financial results for 2020 on January 26, 2021Read More
Featured / May 27
NOVARTIS IN CANADA RESPONDS TO COVID-19 WITH COMMITMENTS IN KEY AREAS Our primary concern at Novartis remains the health and safety of our associates and patients globally, and it is ...Learn More
Our Business
Novartis focuses its business on three leading divisions on a global scale: pharmaceuticals, eye care and generics.Learn More
NOVARTIS CANADA
* Our Work
* Notre travail
* About Us
* À propos de Novartis* Our Products
* Nos Produits
* News
* Actualité
* Careers
* Carrière
* Contact Us
* Sites
* Locations
* Biome Canada, Montreal * Biome Canada, Montreal SUBSCRIBE TO NOVARTIS * Twitter * LINKEDIN* Novartis Site
Directory
2021 Novartis Pharmaceuticals Canada inc. * Terms of Use * Privacy Policy * Cookie Settings This site is intended for an audience in Canada. Facebook Twitter Google+ Pinterest Email LinkedIn Google Gmail AIM Amazon Wish List AOL Mail App.net Baidu Balatarin BibSonomy Bitty Browser Blinklist Blogger Post BlogMarks Bookmarks.fr Box.net BuddyMarks Buffer Care2 News CiteULike Delicious Design Float Diary.Ru Diaspora Digg diHITT Diigo DZone Evernote Fark Flipboard Folkd FriendFeed Google Bookmarks Hacker News Hatena Instapaper Jamespot Kakao Kindle It Line LiveJournal Mail.Ru Mendeley Meneame Mixi Netlog Netvouz NewsTrust NewsVine NUjij Odnoklassniki Outlook.com Pinboard Plurk Pocket Print PrintFriendly Protopage Bookmarks Pusha Qzone Rediff MyPage Renren Segnalo Sina Weibo SiteJot Slashdot Springpad Stumpedia Svejo Symbaloo Feeds Tuenti Twiddla TypePad Post Viadeo VK Wanelo Webnews Wykop XING Yahoo Bookmarks Yahoo Mail Yahoo Messenger Yoolink YouMob Yummly ____AddToAny
Facebook Twitter Google+ Pinterest Email LinkedIn Google Gmail AOL Mail Outlook.com Yahoo Mail Any emailEmail app
More…
COOKIE PREFERENCE CENTER When you visit any website, it may store or retrieve information on your browser by using cookies. The cookies are set to expire when the information is no longer needed or after a maximum period of 13 months. You can choose to allow or not to allow some specific types of cookies. Click on the different category headings below to find out more. Please note that blocking some types of cookies may impact your experience on the site and the services we are able to offer.Acceptall
MANAGE CONSENT PREFERENCES STRICTLY NECESSARY COOKIESAlways Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.Cookies Details
PERFORMANCE COOKIES
Performance cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitorits performance.
Cookies Details
TARGETING COOKIES
Targeting cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.Cookies Details
BACK BUTTON BACK
Vendor Search Search IconFilter Icon
Clear
checkbox label labelApply Cancel
Consent Leg.Interest checkbox label label checkbox label label checkbox label label*
33ACROSS
HOST DESCRIPTION
VIEW COOKIES
*
Name
cookie name
Save choices
YOUR PRIVACY IS IMPORTANT FOR US. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies, select “Cookie settings” for managing the different cookies or select “Reject all” for using only strictly necessary cookies. You can change your cookie settings at any point of time by pressing the cookie settings link on the website. Cookie Settings Reject all Accept allDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0